Ibrutinib
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, B-Cell
Conditions
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Trial Timeline
May 22, 2017 → May 10, 2027
NCT ID
NCT03229200About Ibrutinib
Ibrutinib is a approved stage product being developed by Johnson & Johnson for Lymphoma, B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03229200. Target conditions include Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03476655 | Pre-clinical | Completed |
| NCT03229200 | Approved | Active |
Competing Products
20 competing products in Lymphoma, B-Cell